Multipoint incremental motor unit number estimation as an outcome measure in ALS

J. M. Shefner, M. L. Watson, L. Simionescu, J. B. Caress, T. M. Burns, Nicholas J Maragakis, M. Benatar, W. S. David, K. R. Sharma, S. B. Rutkove

Research output: Contribution to journalArticle

Abstract

Background: Improved outcome measures are necessary to reduce sample size and increase power in amyotrophic lateral sclerosis (ALS) clinical trials. Motor unit number estimation (MUNE) is a potentially attractive tool. MUNE methods previously employed in multicenter trials exhibited excessive variability and were prone to artifact. Objective: To evaluate a modification of standard incremental MUNE in a multicenter natural history study of subjects with ALS. Methods: Fifty healthy subjects were evaluated twice and 71 subjects with ALS were studied repeatedly for up to 500 days. Side and nerve studied was based on clinical examination findings. Nerves were stimulated at 3 specified locations and 3 increments were obtained at each location. Average single motor unit action potential (SMUP) amplitude was calculated by adding the amplitude of the third increment at each location and dividing by 9; SMUP was divided into maximum CMAP amplitude to determine the MUNE. Results: Test-retest variability was 9% in normal subjects. Average MUNE for normal subjects was 225 (±87), and was 41.9 (±39) among subjects with ALS at baseline. Subjects with ALS showed clear decrements over time, with an overage rate of decline of approximately 9% per month. SMUP amplitude increased with time in a fashion consistent with the known pathophysiology of ALS. Conclusion: Multipoint incremental MUNE has a number of attributes that make it attractive as an outcome measure in ALS and other diseases characterized by motor unit loss. It can be rapidly performed on any EMG machine and has repeatability and rates of decline that favorably compare to other previously described methods.

Original languageEnglish (US)
Pages (from-to)235-241
Number of pages7
JournalNeurology
Volume77
Issue number3
DOIs
StatePublished - Jul 19 2011

Fingerprint

Amyotrophic Lateral Sclerosis
Outcome Assessment (Health Care)
Action Potentials
Natural History
Sample Size
Artifacts
Multicenter Studies
Healthy Volunteers
Clinical Trials

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Shefner, J. M., Watson, M. L., Simionescu, L., Caress, J. B., Burns, T. M., Maragakis, N. J., ... Rutkove, S. B. (2011). Multipoint incremental motor unit number estimation as an outcome measure in ALS. Neurology, 77(3), 235-241. https://doi.org/10.1212/WNL.0b013e318225aabf

Multipoint incremental motor unit number estimation as an outcome measure in ALS. / Shefner, J. M.; Watson, M. L.; Simionescu, L.; Caress, J. B.; Burns, T. M.; Maragakis, Nicholas J; Benatar, M.; David, W. S.; Sharma, K. R.; Rutkove, S. B.

In: Neurology, Vol. 77, No. 3, 19.07.2011, p. 235-241.

Research output: Contribution to journalArticle

Shefner, JM, Watson, ML, Simionescu, L, Caress, JB, Burns, TM, Maragakis, NJ, Benatar, M, David, WS, Sharma, KR & Rutkove, SB 2011, 'Multipoint incremental motor unit number estimation as an outcome measure in ALS', Neurology, vol. 77, no. 3, pp. 235-241. https://doi.org/10.1212/WNL.0b013e318225aabf
Shefner, J. M. ; Watson, M. L. ; Simionescu, L. ; Caress, J. B. ; Burns, T. M. ; Maragakis, Nicholas J ; Benatar, M. ; David, W. S. ; Sharma, K. R. ; Rutkove, S. B. / Multipoint incremental motor unit number estimation as an outcome measure in ALS. In: Neurology. 2011 ; Vol. 77, No. 3. pp. 235-241.
@article{1069aa95902646638caa25173289c598,
title = "Multipoint incremental motor unit number estimation as an outcome measure in ALS",
abstract = "Background: Improved outcome measures are necessary to reduce sample size and increase power in amyotrophic lateral sclerosis (ALS) clinical trials. Motor unit number estimation (MUNE) is a potentially attractive tool. MUNE methods previously employed in multicenter trials exhibited excessive variability and were prone to artifact. Objective: To evaluate a modification of standard incremental MUNE in a multicenter natural history study of subjects with ALS. Methods: Fifty healthy subjects were evaluated twice and 71 subjects with ALS were studied repeatedly for up to 500 days. Side and nerve studied was based on clinical examination findings. Nerves were stimulated at 3 specified locations and 3 increments were obtained at each location. Average single motor unit action potential (SMUP) amplitude was calculated by adding the amplitude of the third increment at each location and dividing by 9; SMUP was divided into maximum CMAP amplitude to determine the MUNE. Results: Test-retest variability was 9{\%} in normal subjects. Average MUNE for normal subjects was 225 (±87), and was 41.9 (±39) among subjects with ALS at baseline. Subjects with ALS showed clear decrements over time, with an overage rate of decline of approximately 9{\%} per month. SMUP amplitude increased with time in a fashion consistent with the known pathophysiology of ALS. Conclusion: Multipoint incremental MUNE has a number of attributes that make it attractive as an outcome measure in ALS and other diseases characterized by motor unit loss. It can be rapidly performed on any EMG machine and has repeatability and rates of decline that favorably compare to other previously described methods.",
author = "Shefner, {J. M.} and Watson, {M. L.} and L. Simionescu and Caress, {J. B.} and Burns, {T. M.} and Maragakis, {Nicholas J} and M. Benatar and David, {W. S.} and Sharma, {K. R.} and Rutkove, {S. B.}",
year = "2011",
month = "7",
day = "19",
doi = "10.1212/WNL.0b013e318225aabf",
language = "English (US)",
volume = "77",
pages = "235--241",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Multipoint incremental motor unit number estimation as an outcome measure in ALS

AU - Shefner, J. M.

AU - Watson, M. L.

AU - Simionescu, L.

AU - Caress, J. B.

AU - Burns, T. M.

AU - Maragakis, Nicholas J

AU - Benatar, M.

AU - David, W. S.

AU - Sharma, K. R.

AU - Rutkove, S. B.

PY - 2011/7/19

Y1 - 2011/7/19

N2 - Background: Improved outcome measures are necessary to reduce sample size and increase power in amyotrophic lateral sclerosis (ALS) clinical trials. Motor unit number estimation (MUNE) is a potentially attractive tool. MUNE methods previously employed in multicenter trials exhibited excessive variability and were prone to artifact. Objective: To evaluate a modification of standard incremental MUNE in a multicenter natural history study of subjects with ALS. Methods: Fifty healthy subjects were evaluated twice and 71 subjects with ALS were studied repeatedly for up to 500 days. Side and nerve studied was based on clinical examination findings. Nerves were stimulated at 3 specified locations and 3 increments were obtained at each location. Average single motor unit action potential (SMUP) amplitude was calculated by adding the amplitude of the third increment at each location and dividing by 9; SMUP was divided into maximum CMAP amplitude to determine the MUNE. Results: Test-retest variability was 9% in normal subjects. Average MUNE for normal subjects was 225 (±87), and was 41.9 (±39) among subjects with ALS at baseline. Subjects with ALS showed clear decrements over time, with an overage rate of decline of approximately 9% per month. SMUP amplitude increased with time in a fashion consistent with the known pathophysiology of ALS. Conclusion: Multipoint incremental MUNE has a number of attributes that make it attractive as an outcome measure in ALS and other diseases characterized by motor unit loss. It can be rapidly performed on any EMG machine and has repeatability and rates of decline that favorably compare to other previously described methods.

AB - Background: Improved outcome measures are necessary to reduce sample size and increase power in amyotrophic lateral sclerosis (ALS) clinical trials. Motor unit number estimation (MUNE) is a potentially attractive tool. MUNE methods previously employed in multicenter trials exhibited excessive variability and were prone to artifact. Objective: To evaluate a modification of standard incremental MUNE in a multicenter natural history study of subjects with ALS. Methods: Fifty healthy subjects were evaluated twice and 71 subjects with ALS were studied repeatedly for up to 500 days. Side and nerve studied was based on clinical examination findings. Nerves were stimulated at 3 specified locations and 3 increments were obtained at each location. Average single motor unit action potential (SMUP) amplitude was calculated by adding the amplitude of the third increment at each location and dividing by 9; SMUP was divided into maximum CMAP amplitude to determine the MUNE. Results: Test-retest variability was 9% in normal subjects. Average MUNE for normal subjects was 225 (±87), and was 41.9 (±39) among subjects with ALS at baseline. Subjects with ALS showed clear decrements over time, with an overage rate of decline of approximately 9% per month. SMUP amplitude increased with time in a fashion consistent with the known pathophysiology of ALS. Conclusion: Multipoint incremental MUNE has a number of attributes that make it attractive as an outcome measure in ALS and other diseases characterized by motor unit loss. It can be rapidly performed on any EMG machine and has repeatability and rates of decline that favorably compare to other previously described methods.

UR - http://www.scopus.com/inward/record.url?scp=80051513726&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80051513726&partnerID=8YFLogxK

U2 - 10.1212/WNL.0b013e318225aabf

DO - 10.1212/WNL.0b013e318225aabf

M3 - Article

VL - 77

SP - 235

EP - 241

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 3

ER -